5AM Ventures

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Inipharm Inc. is a biopharmaceutical company based in Bellevue, Washington, established in 2018. The company specializes in discovering and developing therapies for severe liver diseases, particularly nonalcoholic steatohepatitis (NASH). Inipharm focuses on small-molecule drugs that target HSD17B13, a gene linked to various liver conditions. By modulating this gene's activity, Inipharm aims to reduce liver damage, inflammation, and fibrosis, addressing significant unmet medical needs in the treatment of liver diseases.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

PhaseRx is a biopharmaceutical company based in Seattle that focuses on the development of innovative therapies for inherited enzyme deficiencies in the liver. Utilizing its proprietary Hybrid messenger RNA technology platform, PhaseRx aims to provide intracellular enzyme replacement therapy (i-ERT) by enabling the synthesis of essential enzymes directly within cells. The company is developing a portfolio of products targeting specific urea cycle disorders, including ornithine transcarbamylase deficiency, argininosuccinate lyase deficiency, and argininosuccinate synthetase deficiency. Founded by a team with expertise from the University of Washington and Fred Hutchinson Cancer Research Center, PhaseRx leverages novel polymer technology for the delivery of therapeutic agents, including siRNA and other macromolecular therapeutics.